Klozapine Bağlı Sık Görülen Yan Etkiler ve Metabolik Sendrom: Klinik Değişkenlerle ve Yetiyitimiyle İlişkisi
Yıl: 2021 Cilt: 32 Sayı: 2 Sayfa Aralığı: 87 - 99 Metin Dili: Türkçe DOI: 10.5080/u25737 İndeks Tarihi: 07-06-2022
Klozapine Bağlı Sık Görülen Yan Etkiler ve Metabolik Sendrom: Klinik Değişkenlerle ve Yetiyitimiyle İlişkisi
Öz: Amaç: Klozapine bağlı sık görülen yan etkiler tedavi sürecini olumsuz
etkileyebilmektedir. Bu çalışmada klozapin kullanan şizofreni
hastalarında sık görülen yan etkilerin değerlendirilmesi, metabolik
sendrom yaygınlığının saptanması, klinik değişkenlerle ilişkisinin ve
yetiyitimine etkisinin incelenmesi amaçlanmıştır.
Yöntem: Çalışmaya DSM-IV’e göre şizofreni tanısı konulan, klozapin
kullanmakta olan 122 hasta dahil edilmiştir. Hastadan ve hastane
dosyasından alınan bilgiler doğrultusunda klinik bilgiler değerlendirilmiş,
bedensel ölçümler ve laboratuvar değerleri kaydedilmiştir. Hastalara
DSM-IV Eksen I Bozuklukları için Yapılandırılmış Klinik Görüşme
Formu, UKU (Udvalg for Kliniske Undersogelser) Yan Etki
Değerlendirme Ölçeği, Dünya Sağlık Örgütü-Yetiyitimi Değerlendirme
Çizelgesi II, Pozitif ve Negatif Sendrom Ölçeği, Global Değerlendirme
Ölçeği, Klinik Global İzlenim Ölçeği uygulanmıştır.
Bulgular: Sık bildirilen yakınmalar salya artışı, yorgunluk, sedasyon,
kabızlık olarak saptanmış, kabızlık ile klozapin dozu, baş dönmesi
ile norklozapin düzeyi arasında istatistiksel olarak anlamlı ilişki
bulunmuştur. Metabolik sendrom yaygınlığı %50 bulunmuş, metabolik
sendrom olanların yaş ortalamasının daha yüksek, yaşam boyu sigara
kullanımı miktarının daha fazla olduğu görülmüştür. Yetiyitimi
şiddetinin psikopatoloji şiddeti ve yan etki sayısıyla pozitif, hastalık
başlangıç yaşıyla negatif korelasyon gösterdiği, yetiyitimi şiddetini yan
etki sayısı ve psikopatoloji şiddetinin yordadığı saptanmıştır.
Sonuç: Klozapinin geniş bir yan etki profili bulunmakta, hastaların
yarısında metabolik sendrom görülmektedir. Klozapine bağlı sık görülen
yan etkilerin ele alınması, yetiyitiminin azaltılması açısından önemlidir.
Anahtar Kelime: Common Side Effects and Metabolic Syndrome due to Clozapine: Relationship with the Clinical Variables and Disability
Öz: Objective: Common side effects of clozapine may affect the treatment
process negatively. In this study, we aimed to assess the common side
effects and the prevalence of metabolic syndrome in schizophrenia
patients treated with clozapine, and to study their relationship with
clinical variables and disability.
Method: One hundred and twenty two patients who met DSM-IV
criteria for schizophrenia, and were on clozapine treatment were included
in the study. Clinical status was evaluated through a clinical interview
and review of the medical records, and physical measures and laboratory
tests were recorded. Patients were assessed with the Structured Clinical
Interview for DSM-IV Axis I Disorders, UKU (Udvalg for Kliniske
Undersogelser) Side Effect Rating Scale, World Health Organization
(WHO)-Disability Assessment Schedule II, Positive and Negative
Syndrome Scale, Global Assessment Scale, Clinical Global Impression
Scale.
Results: Common side effects of clozapine were hypersalivation, fatigue,
sedation and constipation. The relationship between constipation
and clozapine dose, and dizziness and norclozapine plasma levels
were significant. The prevalence of metabolic syndrome was 50%,
and patients with metabolic syndrome had higher means of age and
lifetime cigarette consumption. Disability was positively correlated
with the severity of psychopathology and the number of side effects,
and negatively correlated with the age at onset of illness. Severity of the
psychopathology and the number of side effects predicted the severity
of the disability.
Conclusion: Clozapine was associated with various side effects and half
of the patients had metabolic syndrome. Assessment of common side
effects due to clozapine is important for reducing disability.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- Anıl Yağcıoğlu AE, Ertuğrul A (2011) Antipsikotik ilaçların kardiyovasküler yan etkileri. Psikiyatride Güncel 1:251-65.
- Asenjo Lobos C, Komossa K, Rummel-Kluge C ve ark. (2010) Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 10:CD006633.
- Bleakley S, Taylor D (2013) The Clozapine Handbook. 1. ed. Warwickshire, Lloyd-Reinhold Communications LLP s. 36 -119.
- Citrome L (2017) Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. J Clin Psychopharmacol 37:138-47.
- Citrome L, McEvoy JP, Saklad SR (2016) Guide to the management of clozapine-related tolerability and safety concerns. Clin Schizophr Relat Psychoses 10:163-77.
- Cornier MA, Dabelea D, Hernandez TL ve ark. (2008) The metabolic syndrome. Endocr Rev 29:777-822.
- De Berardis D, Rapini G, Olivieri L ve ark. (2018) Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Ther Adv Drug Saf 9:237-56.
- De Hert M, Hudyana H, Dockx L ve ark. (2011) Second-generation antipsychotics and constipation: a review of the literature. Eur Psychiatry 26: 34-44.
- De Leon J, Armstrong SC, Cozza KL (2005) The dosing of atypical antipsychotics. Psychosomatics 46:262-73.
- De Leon J, Odom-White A, Josiassen RC ve ark. (2003) Serum antimuscarinic activity during clozapine treatment. J Clin Psychopharmacol 23:336–41.
- Endicott J, Spitzer R, Fleiss J ve ark. (1976) The global assessment scale. Arch Gen Psychiatry 33:766-71.
- Ertuğrul A, Uluğ B (2002) The influence of neurocognitive deficits and symptoms on disability in schizophrenia. Acta Psychiatr Scand 105:196- 201.
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–97
- First MB, Spitzer RL, Gibbon M ve ark. (1997) DSM-IV Eksen I Bozuklukları İçin Yapılandırılmış Klinik Görüşme (SCID-I/CV) (Çev.: A. Çorapçıoğlu).
- Ankara, Hekimler Yayın Birliği, Ankara, 1999.
- Fukuda K, Straus SE, Hickie I ve ark. (1994) The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 121:953-9.
- Grundy SM, Brewer B, Cleeman JL ve ark. (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/ American Heart Association Conference on scientific issues related to definition. Circulation 109:433–8
- Gugger JJ, Ehret MJ (2016) Chapter 4 - Orthostatic Hypotension. Lifethreatening effects of antipsychotic drugs, 1. Baskı, Manu P, Flanagan RJ, Ronaldson KJ (Ed), San Diego, Academic Press, s. 81 - 101
- Guy, W. (1976) ECDEU assessment manual for psychopharmacology-revised (DHEW Publ No ADM 76-338), MD, US Department of Health, Education, and Welfare. Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville,1076, s. 217-22.
- Harrison-Woolrych M, Skegg K, Ashton J ve ark. (2011) Nocturnal enuresis in patients taking clozapine, risperidone, olanzapine and quetiapine: comparative cohort study. Br J Psychiatry 199:140-4.
- Harvey PD, Strassnig MT, Silberstein J (2019) Prediction of disability in schizophrenia: Symptoms, cognition, and self-assessment. J Exp Psychopathol 10:1–20
- Henderson DC, Cagliero E, Gray C ve ark. (2000) Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 157:975-81.
- Hirsch L, Yang J, Bresee L ve ark. (2017) Second generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf 40:771–81.
- International Diabetes Federation (2005) The IDF Consensus Worldwide Definition of the Metabolic Syndrome. International Diabetes Federation, Brussels
- Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-75.
- Kishi T, Fujita K, Furukawa O ve ark. (2013) Efficacy and tolerability of clozapine in Japanese patients with treatment resistant schizophrenia: results from a 12-week, flexible dose study using raters masked to antipsychotic choice. Asian J Psychiatr 6:200-7
- Kostakoğlu AE, Batur S, Tiryaki A ve ark. (1999) Pozitif ve negatif sendrom ölçeğinin (PANSS) Türkçe uyarlamasının geçerlilik ve güvenilirliği. Türk Psikoloji Dergisi 14:23-32.
- Lamberti JS, Olson D, Crilly JF ve ark. (2006) Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 163:1273-6.
- Lameh J, Burstein ES, Taylor E, ve ark. (2007) Pharmacology of N-desmethylclozapine. Pharmacol Ther 115:223–31.
- Leucht S, Cipriani A, Spineli L ve ark. (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 382:951–62.
- Lin CC, Bai YM, Chen JY (1999) A retrospective study of clozapine and urinary incontinence in Chinese in-patients. Acta Psychiatr Scand 100:158-61.
- Lingjaerde O, Ahlfors UG, Bech P ve ark. (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a crosssectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 334:1-100.
- Mackin P (2008) Cardiac side effects of psychiatric drugs. Hum Psychopharmacol 23 (Suppl. 1):3-14.
- Maher S, Cunningham A, O’Callaghan N ve ark. (2016) Clozapine‐induced hypersalivation: an estimate of prevalence, severity and impact on quality of life. Ther Adv Psychopharmacol 6:178‐84.
- McEvoy JP, Lieberman JA, Stroup TS ve ark. (2006) CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600-10.
- McKibbin C, Patterson TL, Jeste DV (2004) Assessing disability in older patients with schizophrenia: results from the WHODAS-II. J Nerv Ment Dis 192:405-13.
- Miller DD (2000) Review and management of clozapine side effects. J Clin Psychiatry 61 (Suppl. 8):14-7.
- Naber D, Moritz S, Lambert M ve ark. (2001) Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophr Res 30;50:79-88.
- Olianas MC, Dedoni S, Ambu R ve ark. (2009) Agonist activity of n-desmethylclozapine at δ-opioid receptors of human frontal cortex. Eur J Pharmacol 607:96–101.
- Özkürkçügil A, Aydemir Ö, Yıldız M ve ark. (1999) DSM-IV eksen I bozuklukları için yapılandırılmış klinik görüşmenin Türkçeye uyarlanması ve güvenilirlik çalışması. İlaç ve Tedavi Dergisi 12:233-6.
- Palmer SE, McLean RM, Ellis PM ve ark. (2008) Life-threatening clozapineinduced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry 69:759-68.
- Papanastasiou E (2013) The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review. Ther Adv Psychopharmacol 3:33-51.
- Praharaj SK, Arora M, Gandotra S (2006) Clozapine-induced sialorrhea: pathophysiology and management strategies. Psychopharmacology (Berl) 185:265-73.
- Raedler TJ (2010) Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry 23:574-81.
- Ramos Perdigués S, Sauras Quecuti R, Mané A ve ark. (2016) An observational study of clozapine induced sedation and its pharmacological management. Eur Neuropsychopharmacol 26:156-61.
- Remington G, Agid O, Foussias G, ve ark. (2013) Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology (Berl) 225:505-18.
- Remington G, Lee J, Agid O ve ark. (2016) Clozapine’s critical role in treatment resistant schizophrenia: ensuring both safety and use. Expert Opin Drug Saf 15:1193–203.
- Rostagno C, Domenichetti S, Pastorelli F ve ark. (2011) Usefulness of NT-pro- BNP and echocardiography in the diagnosis of subclinical clozapine-related cardiotoxicity. J Clin Psychopharmacol 31:712–6.
- Rummel-Kluge C, Komossa K, Schwarz S ve ark. (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 123:225-33.
- Schorr SG, Sloof CJ, Bruggeman R ve ark. (2009) The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year. J Psychiatr Res 43:1106–11
- Shirazi A, Stubbs B, Gomez L ve ark. (2016) Prevalence and Predictors of Clozapine-Associated Constipation: A Systematic Review and Meta- Analysis. Int J Mol Sci 17:863.
- Simon V, van Winkel R, De Hert M (2009) Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 70:1041-50.
- Sockalingam S, Shammi C, Remington G (2007) Clozapine-induced hypersalivation: a review of treatment strategies. Can J Psychiatry 52:377-84.
- Solmi M, Murru A, Pacchiarotti I ve ark. (2017) Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-theart clinical review. Ther Clin Risk Manag 13:757–77.
- Stroup TS, Lieberman JA, McEvoy JP ve ark. (2009) Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 107:1–12.
- Switaj P, Anczewska M, Chrostek A ve ark. (2012) Disability and Schizophrenia: A Systematic Review of Experienced Psychosocial Difficulties. BMC Psychiatry 12:193.
- Syed R, Au K, Cahill C, Duggan L ve ark. (2008) Pharmacological interventions for clozapine-induced hypersalivation. Cochrane Database Syst Rev 16:CD005579.
- Taylor D, Paton C, Kapur S (2015) Maudsley Prescribing Guidelines. 12. ed. Oxford, Wiley-Blackwell. s. 165-81
- Uluğ B, Ertuğrul A, Göğüş A, Kabakçı E (2001) Yetiyitimi değerlendirme çizelgesinin (WHO-DAS-II) şizofreni hastalarında geçerlilik ve güvenilirliği. Turk Psikiyatri Derg 12:121-30.
- Waters F, Naik N, Rock D (2013) Sleep, fatigue, and functional health in psychotic patients. Schizophr Res Treatment 2013: 425826.
- Wetterling T (2001) Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 24:59-73.
- World Health Organization (2011) Clozapine and life-threatening gastrointestinal hypomotility. WHO Drug Information 25:29-30.
- World Health Organization (2011) World report on disability 2011. 10 Mayıs 2020’de https://www.who.int/disabilities/world_report/2011/report.pdf adresinden indirilmiştir.
- Yazıcı MK, Anıl Yağcıoğlu AE, Ertuğrul A ve ark. (2011) The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey. Eur Arch Psychiatry Clin Neurosci 261: 69-78.
- Yoca G, Anıl Yağcıoğlu AE, Eni N ve ark. (2019) A follow-up study of metabolic syndrome in schizophrenia. Eur Arch Psychiatry Clin Neurosci 27 Nisan 2019, çevrimiçi yayın.
- Yusufi B, Mukherjee S, Flanagan R ve ark. (2007) Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopharmacol 22:238–43
- Zhu S, St-Onge MP, Heshka S ve ark. (2004) Lifestyle behaviors associated with lower risk of having the metabolic syndrome. Metabolism 53:1503-11.
- Zipursky RB, Reilly TJ, Murray RM (2013) The myth of schizophrenia as a progressive brain disease. Schizophr Bull 39:1363–72.
| APA | Gürcan G, Hun Senol S, ANIL YAGCIOGLU A, Karahan S, ERTUGRUL A (2021). Klozapine Bağlı Sık Görülen Yan Etkiler ve Metabolik Sendrom: Klinik Değişkenlerle ve Yetiyitimiyle İlişkisi. , 87 - 99. 10.5080/u25737 |
| Chicago | Gürcan Gamze,Hun Senol Sevin,ANIL YAGCIOGLU A. ELIF,Karahan Sevilay,ERTUGRUL Aygün Klozapine Bağlı Sık Görülen Yan Etkiler ve Metabolik Sendrom: Klinik Değişkenlerle ve Yetiyitimiyle İlişkisi. (2021): 87 - 99. 10.5080/u25737 |
| MLA | Gürcan Gamze,Hun Senol Sevin,ANIL YAGCIOGLU A. ELIF,Karahan Sevilay,ERTUGRUL Aygün Klozapine Bağlı Sık Görülen Yan Etkiler ve Metabolik Sendrom: Klinik Değişkenlerle ve Yetiyitimiyle İlişkisi. , 2021, ss.87 - 99. 10.5080/u25737 |
| AMA | Gürcan G,Hun Senol S,ANIL YAGCIOGLU A,Karahan S,ERTUGRUL A Klozapine Bağlı Sık Görülen Yan Etkiler ve Metabolik Sendrom: Klinik Değişkenlerle ve Yetiyitimiyle İlişkisi. . 2021; 87 - 99. 10.5080/u25737 |
| Vancouver | Gürcan G,Hun Senol S,ANIL YAGCIOGLU A,Karahan S,ERTUGRUL A Klozapine Bağlı Sık Görülen Yan Etkiler ve Metabolik Sendrom: Klinik Değişkenlerle ve Yetiyitimiyle İlişkisi. . 2021; 87 - 99. 10.5080/u25737 |
| IEEE | Gürcan G,Hun Senol S,ANIL YAGCIOGLU A,Karahan S,ERTUGRUL A "Klozapine Bağlı Sık Görülen Yan Etkiler ve Metabolik Sendrom: Klinik Değişkenlerle ve Yetiyitimiyle İlişkisi." , ss.87 - 99, 2021. 10.5080/u25737 |
| ISNAD | Gürcan, Gamze vd. "Klozapine Bağlı Sık Görülen Yan Etkiler ve Metabolik Sendrom: Klinik Değişkenlerle ve Yetiyitimiyle İlişkisi". (2021), 87-99. https://doi.org/10.5080/u25737 |
| APA | Gürcan G, Hun Senol S, ANIL YAGCIOGLU A, Karahan S, ERTUGRUL A (2021). Klozapine Bağlı Sık Görülen Yan Etkiler ve Metabolik Sendrom: Klinik Değişkenlerle ve Yetiyitimiyle İlişkisi. Türk Psikiyatri Dergisi, 32(2), 87 - 99. 10.5080/u25737 |
| Chicago | Gürcan Gamze,Hun Senol Sevin,ANIL YAGCIOGLU A. ELIF,Karahan Sevilay,ERTUGRUL Aygün Klozapine Bağlı Sık Görülen Yan Etkiler ve Metabolik Sendrom: Klinik Değişkenlerle ve Yetiyitimiyle İlişkisi. Türk Psikiyatri Dergisi 32, no.2 (2021): 87 - 99. 10.5080/u25737 |
| MLA | Gürcan Gamze,Hun Senol Sevin,ANIL YAGCIOGLU A. ELIF,Karahan Sevilay,ERTUGRUL Aygün Klozapine Bağlı Sık Görülen Yan Etkiler ve Metabolik Sendrom: Klinik Değişkenlerle ve Yetiyitimiyle İlişkisi. Türk Psikiyatri Dergisi, vol.32, no.2, 2021, ss.87 - 99. 10.5080/u25737 |
| AMA | Gürcan G,Hun Senol S,ANIL YAGCIOGLU A,Karahan S,ERTUGRUL A Klozapine Bağlı Sık Görülen Yan Etkiler ve Metabolik Sendrom: Klinik Değişkenlerle ve Yetiyitimiyle İlişkisi. Türk Psikiyatri Dergisi. 2021; 32(2): 87 - 99. 10.5080/u25737 |
| Vancouver | Gürcan G,Hun Senol S,ANIL YAGCIOGLU A,Karahan S,ERTUGRUL A Klozapine Bağlı Sık Görülen Yan Etkiler ve Metabolik Sendrom: Klinik Değişkenlerle ve Yetiyitimiyle İlişkisi. Türk Psikiyatri Dergisi. 2021; 32(2): 87 - 99. 10.5080/u25737 |
| IEEE | Gürcan G,Hun Senol S,ANIL YAGCIOGLU A,Karahan S,ERTUGRUL A "Klozapine Bağlı Sık Görülen Yan Etkiler ve Metabolik Sendrom: Klinik Değişkenlerle ve Yetiyitimiyle İlişkisi." Türk Psikiyatri Dergisi, 32, ss.87 - 99, 2021. 10.5080/u25737 |
| ISNAD | Gürcan, Gamze vd. "Klozapine Bağlı Sık Görülen Yan Etkiler ve Metabolik Sendrom: Klinik Değişkenlerle ve Yetiyitimiyle İlişkisi". Türk Psikiyatri Dergisi 32/2 (2021), 87-99. https://doi.org/10.5080/u25737 |
